Researchers at Evotec have developed a humanized mouse model that shows robust signs of colitis, providing a valuable tool for assessing the efficacy of human-specific antibodies and other biologics. This innovative approach increases clinical translation and offers new insights into the treatment of IBD.

Key findings include:

• Dose-dependent effects: DSS treatment in BRGSF-HIS mice induced dose-dependent effects on disease activity index scores, human proinflammatory cytokines, and histopathology scores.
• Colitis induction: Despite the low percentage of myeloid cells, DSS treatment induced and maintained colitis until Day 7.
• Clinical relevance: This model allows for direct assessment of human-specific treatments, enhancing the potential for effective therapies.